Emerging research has illuminated the role of tumor-derived EVPs in the establishment of pre-metastatic niches (PMNs) within distant organs. This process involves the selective priming of remote tissues, effectively conditioning them to support the colonization and outgrowth of metastatic cancer cells. EVPs deliver a cargo comprised of proteins, lipids, and nucleic acids that remodel the extracellular matrix, modulate local immune cell populations, and influence stromal cell behavior. Through these multifaceted mechanisms, EVPs not only facilitate metastatic dissemination but also engender significant immune dysregulation within PMNs, undermining the organ-specific defenses that would ordinarily impede tumor cell invasion.

Moreover, cancer-associated EVPs are implicated in systemic complications that extend into the realms of thrombosis and cardiovascular disease. The pro-coagulant nature of certain EVP populations contributes to the heightened risk of thrombotic events observed in cancer patients, a leading cause of morbidity and mortality. These vesicles modulate endothelial function, platelet aggregation, and coagulation cascades, creating a prothrombotic milieu. Concurrent cardiovascular impairment further exemplifies the broad-reaching consequences of EVP-mediated intercellular communication, linking tumor biology with systemic vascular pathology in an intricate interplay that exacerbates patient outcomes.

Beyond the vascular system, tumor-secreted EVPs exert profound effects on hepatic metabolism. The liver, a central hub for metabolic regulation, becomes a target for EVP-induced reprogramming that disrupts lipid and glucose processing. This hepatic dysfunction manifests as metabolic derangements with systemic repercussions, including insulin resistance and altered energy homeostasis. These pathophysiological changes underpin various cancer-associated metabolic syndromes, highlighting the liver’s vulnerability to EVP-driven remodeling and underscoring the systemic nature of oncogenic signaling facilitated by these vesicles.

In parallel, the influence of cancer-associated EVPs extends to glucose metabolism disorders, compounding the metabolic dysregulation stemming from hepatic impairment. Tumor-derived EVPs impact pancreatic beta cell function and systemic insulin sensitivity, promoting hyperglycemia and fostering an environment that supports tumor growth. This bidirectional metabolic crosstalk exemplifies a vicious cycle wherein cancer progression and metabolic disease synergistically exacerbate one another, emphasizing the need for holistic therapeutic interventions that address both oncologic and metabolic derangements.

Cachexia, a debilitating wasting syndrome characterized by severe muscle and adipose tissue loss, is another devastating paraneoplastic consequence propelled by EVP activity. EVPs carry factors that drive systemic inflammation and catabolic signaling pathways, accelerating tissue degradation and impairing anabolism. This multifactorial syndrome impacts quality of life and survival, illustrating the catastrophic systemic reach of EVPs beyond the tumor microenvironment into whole-body homeostasis.

Distinct from these metabolic and inflammatory manifestations are paraneoplastic syndromes targeting the nervous system, wherein EVP-mediated communication perturbs neural function and induces neurological deficits. The transport of neurotoxic or immune-modulating cargo by cancer-secreted vesicles contributes to neural damage, cognitive impairment, and neuropathies, underscoring the neurobiological dimension of EVP-related systemic pathology. This expands the clinical frontiers of cancer’s influence, revealing previously underappreciated mechanisms of neural-endocrine disruption.

The complexity of EVP-mediated systemic effects is further amplified by the dynamic interactions involving host-, diet-, and microbiota-derived EVPs. These various extracellular vesicle populations engage in a sophisticated interplay with tumor cells, influencing cancer progression and therapeutic resistance. Dietary components and microbial communities modulate EVP composition and function, integrating environmental factors into the tumor-host dialogue. This intricate network mediates response variability and opens avenues for microbiota-targeted and nutritional strategies aimed at modulating EVP profiles to improve treatment outcomes.

Therapeutically, EVPs present both challenges and opportunities. Their role as mediators of systemic dysfunction makes them compelling targets for intervention, with prospects ranging from inhibiting deleterious vesicle release to harnessing EVPs as delivery vehicles for anti-cancer agents. Engineering EVPs to carry immunomodulatory or cytotoxic payloads represents a promising frontier in systemic cancer therapy, potentially enabling precision targeting of both tumors and their systemic sequelae. However, the complex biology of EVPs demands nuanced approaches that consider their diverse origins, cargo heterogeneity, and functional versatility.

The recognition of cancer as a systemic disease, orchestrated in part through EVP-mediated inter-organ communication, mandates a paradigm shift in oncologic treatment approaches. Traditional strategies focusing solely on tumor eradication fall short of addressing the multifaceted systemic perturbations driven by EVP signaling. A holistic approach, targeting not only the localized tumor but also its systemic metabolic, immunological, and neurological consequences, offers a more comprehensive model for improving patient prognosis and quality of life.

Future research aims to delineate the precise molecular mechanisms governing EVP biogenesis, cargo selection, and uptake, as well as their specific roles in various organ systems. This knowledge will enhance the development of biomarkers for early detection, prognostication, and the monitoring of systemic disease burden. Implementing EVP profiling in clinical settings could transform personalized medicine by enabling tailored interventions that counteract systemic effects while optimizing anti-tumor efficacy.

The systemic health alterations promoted by EVPs extend beyond mere clinical symptoms; they represent fundamental disruptions in cellular communication networks that maintain organismal equilibrium. Understanding these disruptions at a molecular and cellular level unravels the complexity of cancer pathophysiology and highlights novel therapeutic vulnerabilities. Integrating insights from EVP biology into clinical oncology holds promise for not only extending survival but also mitigating the multifactorial burdens of cancer-associated comorbidities.

In summary, the systemic impact of cancer-associated extracellular vesicles and particles embodies a transformative area of oncology research, unveiling the far-reaching influence of tumors on host physiology. These findings compel a re-evaluation of cancer from a localized disease to a multifaceted systemic disorder, driven by intricate EVP networks that foster metastasis, metabolic derangements, immune escape, and organ dysfunction. Holistic treatment paradigms that address this complexity through the modulation or exploitation of EVPs could revolutionize cancer therapy and improve comprehensive patient care.

As investigations continue, the intersection of EVP biology with immunology, metabolism, neurology, and microbiome science promises to yield integrated strategies that combat the systemic consequences of cancer. Leveraging the dual roles of EVPs—as both disease mediators and therapeutic tools—could unlock novel clinical avenues for managing cancer’s broad assault on human health. This evolving understanding ultimately underscores the necessity to transcend tumor-centric models and embrace systemic frameworks that encompass the full spectrum of cancer’s impact.

In this new era of oncology, where extracellular vesicles and particles emerge as both villains and potential heroes, a more nuanced appreciation of cancer’s systemic nature propels scientific discovery and therapeutic innovation. The future of cancer treatment lies in unraveling these complex vesicular communications that transcend traditional boundaries, paving the way for interventions that restore homeostasis, thwart metastasis, and enhance survival. This holistic vision heralds a paradigm shift, positioning extracellular vesicles and particles at the forefront of systemic cancer biology and clinical therapeutics.

Subject of Research: Systemic effects of cancer-associated extracellular vesicles and particles (EVPs) on host tissues, organ dysfunction, cancer progression, and therapeutic applications.

Article Title: Systemic health impact of cancer-associated extracellular vesicles and particles

Article References:

Wang, G., Lucotti, S., Bojmar, L. et al. Systemic health impact of cancer-associated extracellular vesicles and particles.
Nat Rev Cancer (2026). https://doi.org/10.1038/s41568-026-00952-w

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00952-w

Keywords: extracellular vesicles, cancer, systemic disease, metastasis, pre-metastatic niche, metabolic dysfunction, immune dysregulation, thrombosis, cachexia, paraneoplastic syndromes, tumor microenvironment, microbiota, therapeutic EVPs

The research, published in Nature Communications, delineates how migrasome-mediated transport of PTGES fundamentally remodels the local inflammatory microenvironment to favor carcinogenesis. PTGES, or prostaglandin E synthase, is the pivotal enzyme responsible for the final step in PGE2 biosynthesis. PGE2 is a potent bioactive lipid involved in modulating inflammation, immune responses, and tumorigenesis. By focusing on macrophages expressing SPP1, the team identified a cell population with enhanced pro-tumoral features. These SPP1-positive macrophages, upon receiving migrasome-borne PTGES, escalate their production of PGE2, which in turn drives a cascade of signaling events that promote abnormal epithelial cell proliferation and survival, fueling lesion progression.

This mechanistic insight into how migrasomes serve as vehicles ferrying PTGES challenges the traditional view of extracellular vesicles. Previously overshadowed by exosomes and microvesicles, migrasomes have now emerged as critical mediators in the orchestration of complex intercellular communication networks within the tumor microenvironment. Their unique biogenesis, linked to migrating cells shedding small vesicles from retraction fibers, facilitates targeted delivery of enzymatic cargo to recipient cells, thereby modulating their phenotype and function. This specificity could offer unprecedented therapeutic opportunities by interfering with migrasome formation or cargo loading to disarm pro-carcinogenic signaling.

The team’s multidisciplinary approach combined advanced imaging techniques, single-cell transcriptomics, and in vivo models to verify the role of migrasomal PTGES transfer. High-resolution confocal microscopy visualized migrasomes emerging from migrating keratinocytes in the oral mucosa, while flow cytometry and RNA sequencing isolated and characterized SPP1-positive macrophage populations. Importantly, genetic manipulation experiments demonstrated that silencing PTGES within migrasomes or depleting SPP1 expression in macrophages significantly attenuated PGE2 production and reduced oral leukoplakia lesion size and malignant transformation rates in animal models.

Inflammation is a well-established driver in cancer progression, and the PGE2 pathway’s involvement in chronic inflammation’s transition to malignancy is widely recognized. However, this study elucidates a previously unappreciated layer of regulation wherein migrasomes act not merely as passive carriers but as active amplifiers of inflammatory signals. Through this, the research underscores the intricate spatial dynamics of signaling molecules within the tumor microenvironment, highlighting that the mere presence of pro-inflammatory mediators is insufficient without the precise cellular context and delivery mechanisms that confer pathogenic potency.

Moreover, the identification of SPP1 as a marker and functional modulator of macrophages elevates its significance beyond a simple biomarker. SPP1, or osteopontin, is increasingly seen as a driver of immune cell plasticity, promoting a pro-tumoral phenotype characterized by immunosuppression, angiogenesis, and matrix remodeling. The interaction between migrasome-transferred PTGES and SPP1 expression synergizes to produce a vicious cycle of PGE2 production, creating a conducive niche for tumor initiation and progression. Targeting this axis could help recalibrate macrophage function from tumor-promoting to tumor-suppressing.

The clinical implications of this discovery are profound. Oral leukoplakia remains a clinical challenge due to its unpredictable malignant potential and lack of effective targeted therapies. By focusing on the migrasome-PTGES-SPP1 macrophage axis, future interventions might employ inhibitors of migrasome formation, PTGES enzymatic activity, or SPP1 signaling pathways to halt or reverse carcinogenesis. These strategies could complement existing modalities such as surgical excision and chemoprevention, ultimately reducing the burden of oral cancers which constitute a significant global health issue.

Beyond oral cancer, these findings may have broader ramifications for other inflammation-driven cancers where PGE2 signaling and macrophage polarization play key roles—such as colorectal, breast, and lung cancers. Migrasomes could represent a ubiquitous and underexplored mode of enzyme delivery and signal amplification across multiple tumor types and other chronic inflammatory diseases, warranting expansive research into their biology and therapeutic exploitation.

The study also sparks intriguing questions about migrasomal cargo specificity and how different cell types might package distinct molecular profiles depending on their activation or pathological state. Understanding the regulatory pathways governing migrasome formation and targeting might reveal novel biomarkers for early cancer detection or prognostication. Moreover, exploring how migrasomes influence immune crosstalk beyond macrophages—potentially involving T cells, fibroblasts, or endothelial cells—could illuminate complex cellular interactions within the tumor niche.

This transformative research provides a conceptual framework that blends cell biology, immunology, and cancer pathophysiology. It redefines the landscape of extracellular vesicle research by incorporating migrasomes as critical players in disease progression. Furthermore, it exemplifies the power of integrating cutting-edge imaging and omics technologies to dissect intercellular communication at an unprecedented resolution.

The implications of migrasomal transport of PTGES extend beyond the molecular level, touching upon fundamental principles of cellular cooperation during carcinogenesis. It highlights how migrating epithelial cells and immune cells do not act in isolation but form a dynamic, interconnected ecosystem where vesicle-mediated exchange influences the trajectory of disease. An appreciation of this complexity is essential for the next generation of cancer therapies, which must address both the tumor cells and their microenvironment.

In summary, the landmark study reveals how migrasomal delivery of PTGES into SPP1-positive macrophages amplifies the PGE2 cascade, potentiating the carcinogenic transformation of oral leukoplakia. This discovery opens new avenues for targeted intervention and reshapes our understanding of inflammation-driven cancer progression. It heralds a new era in which deciphering the language of migrasomes could unlock innovative diagnostics and therapies not only for oral cancer but potentially for a broad spectrum of inflammatory diseases and malignancies.

Subject of Research: Cellular mechanisms driving oral leukoplakia carcinogenesis, focusing on migrasome-mediated PTGES transport and its effect on PGE2 signaling in SPP1-positive macrophages.

Article Title: Migrasome-transported PTGES amplifies the PGE2 cascade in SPP1⁺ macrophages to drive oral leukoplakia carcinogenesis.

Article References:
Jiang, MJ., Zhou, HY., Bai, YT. et al. Migrasome-transported PTGES amplifies the PGE2 cascade in SPP1⁺ macrophages to drive oral leukoplakia carcinogenesis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70824-2

Image Credits: AI Generated